ReviewNature reviews. Endocrinology2023
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
Review in Nature reviews. Endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Consensus guideline for the diagnosis and management of pituitary adenomas in childhood and adolescence: Part 1, general recommendations.Nature reviews. Endocrinology · 2024Guideline
- Article
- Approach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
- Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement.Nature reviews. Endocrinology · 2026Review
- Pathogenesis of nonfamilial somatotroph adenomas.The Journal of clinical endocrinology and metabolism · 2026Review
- External validation of the PANOMEN-3 classification for predicting 1-year surgical remission in pituitary adenoma.Pituitary · 2026Article
- To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly.Pituitary · 2026Review
- Molecular biology of pituitary neuroendocrine tumors.Journal of neuro-oncology · 2026Review
- Association between the WHO 2017 and 2022 classification updates and ICD-10 code accuracy in patients with PitNETs: a real-world retrospective study.BMC endocrine disorders · 2026Article
- Article
- Clinical, radiological, and pathological characteristics and long-term outcomes of silent corticotroph adenomas: a retrospective study.BMC endocrine disorders · 2025Article
- Predictors of progression after surgery in non-functioning pituitary macroadenomas: a Spanish multicenter study.Journal of endocrinological investigation · 2025Article
- Patient perceptions of pituitary incidentaloma diagnosis and follow-up: a Pituitary Society international patient survey.Pituitary · 2025Article
- DNA methylation profiling of pituitary neuroendocrine tumors identifies distinct clinical and pathological subtypes based on epigenetic differentiation.Neuro-oncology · 2025Article
- Observational
- PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study.Endocrine · 2025Article
- Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice.Neuro-oncology advances · 2025Article
- Pituitary adenomas: biology, nomenclature and clinical classification.Reviews in endocrine & metabolic disorders · 2025Review
- New Pituitary Adenoma Classification System to Individualise Management and Improve Long-Term Prognosis.Clinical endocrinology · 2025Article
- A broader outlook is required to stage and classify pituitary neoplasms for patient care.Brain pathology (Zurich, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tumours (NETs). This change confers an oncology label to neoplasms that are overwhelmingly benign. A comprehensive clinical classification schema is required to guide prognosis, therapy and outcomes for all patients with pituitary adenomas. Pituitary adenomas and NETs exhibit some morphological and ultrastructural similarities. However, unlike NETs, pituitary adenomas are highly prevalent, yet indolent and rarely become malignant. This Perspective presents the outcomes of an interdisciplinary international workshop that addressed the merit and clinical implications of the classification change of pituitary adenoma to NET. Many non-histological factors provide mechanistic insight and influence the prognosis and treatment of pituitary adenoma. We recommend the development of a comprehensive classification that integrates clinical, genetic, biochemical, radiological, pathological and molecular information for all anterior pituitary neoplasms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.